Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

PPair-wise comparisonA1C, %6.4 ± 1.45.5 ± 1 < 0.0010.41AST, U/L25.9 ± 1822.5 ± 24.3 < 0.0010.270ALT, U/L33.4 ± 2025.8 ± 27.1 < 0.0010.140GGT, U/L68.8 ± 8029.3 ± 30 < 0.0010.890CRP, mg/dl13.5 ± 117 ± 6 < 0.0010.170LDL, mg/dl105 ± 3293.9 ± 33 < 0.0010.057HDL, mg/dl43.8 ± 1259.3 ± 18 < 0.0010.030NASH versus No NASH (P = 0.001)NASH versus BD NASH (P = 0.017)No NASH versus BD NASH (P = 0.497)Triglyceride, mg/dl209 ± 108149.8 ± 99 < 0.0010.041NASH versus No NASH (P = 0.035)NASH versus BD NASH (P = 0.202)No NASH versus BD NASH (P = 0.286)Cholesterol, mg/dl189 ± 38180.5 ± 36.20.0060.039NASH versus No NASH (P = 0.309)NASH versus BD NASH (P = 0.011)No NASH versus BD NASH (P = 0.098)Folic acid, µg/l7.9 ± 510.4 ± 6.1 < 0.0010.980Vitamin B12, ng/l522.5 ± 234564.5 ± 2970.290.690Vitamin D, µg/l12.2 ± 725.8 ± 11.6 < 0.0010.013NASH versus No NASH (P = 0.004)NASH versus BD NASH (P = 0.086)No NASH versus BD NASH (P = 0.849)p indicates significance according to the Wilcoxon Test, A1C (normal < 6.5%); ALT, alanine aminotransferase (normal 10 to 35 U/L); AST, aspartate aminotransferase (normal 10 to 35 U/L); CRP, C-reactive protein (normal < 5 mg/L); serum triglycerides (normal, 70 to 180 mg/dL); total cholesterol (normal 150 to 200 mg/dl); HDL, high density lipoprotein (normal 45 to 65 mg/dl); LDL, low density lipoprotein (normal < 150 mg/dl); folic acid (normal 4.6 to 18.7 µg/l); Vitamin B-12 (normal 270-730 ng/l); 1,25(OH)-D-Vitamin D (calcitriol) (normal > 30 pg/ml); BD, Borderline; Wilcoxon test compared numerical variables in the whole population before and after surgery.

Source: Weight loss and resolution of comorbidities at follow-up concerning NAFLD. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The Effect of Non-Alcoholic Fatty Liver Disease on Weight Loss and Resolution of Obesity-Related Disorders After Bariatric Surgery

Study design awaiting verification · World Journal of Surgery · 2023

Original publication title

The Effect of Non-Alcoholic Fatty Liver Disease on Weight Loss and Resolution of Obesity-Related Disorders After Bariatric Surgery

Thaer S. A. Abdalla; Anastasios D. Giannou; Ahmed S. A. Abdalla; Jakob R. Izbicki; Anna Dupreé; Oliver Mann; Stefan Wolter

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The beneficial effects of bariatric surgery are evident across all patients with NAFLD. Patients with NASH have comparable outcomes regarding weight loss and resolution of obesity-related comorbidities.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Patients undergoing bariatric surgery have a high incidence of non-alcoholic fatty liver disease (NAFLD). However, the effect of NAFLD or non-alcoholic steatohepatitis (NASH) on the weight loss and resolution of obesity-related disorders is a matter of debate.

Source: Background

Abstract: What methods does the paper describe?

In this study, we compare the long-term outcomes after bariatric with the presence of NAFLD in the liver biopsy at the time of surgery.

Source: Methods

Abstract: Results

The follow-up was available for 226 out of 288 patients. The mean follow-up time was 24.9 (± 13.6) months. The baseline histology showed that 112 patients (38.9%) had no NASH, 70 (24.3%) were borderline, and 106 (36.8%) had NASH. At follow-up, the mean BMI dropped from (52 ± 10.2) to (36.6 ± 8) kg/m 2. Excess weight loss (EWL) was similar in all NAFLD groups. Type 2 diabetes mellitus dropped from 35.7 to 11.4%, hypertension from 65.6 to 36.7%, hyperlipidemia from 62.3 to 33%, and obstructive sleep apnea from 37.5 to 14.9%.

Only hyperlipidemia was significantly associated with NASH compared to the groups with no NASH or borderline NASH (p value = 0.002 and p value = 0.04, respectively) during the first two years of follow-up.

Source: Results

Abstract: Conclusion

The beneficial effects of bariatric surgery are evident across all patients with NAFLD. Patients with NASH have comparable outcomes regarding weight loss and resolution of obesity-related comorbidities.

Source: Conclusion
Authors’ abstract

Background

Patients undergoing bariatric surgery have a high incidence of non-alcoholic fatty liver disease (NAFLD). However, the effect of NAFLD or non-alcoholic steatohepatitis (NASH) on the weight loss and resolution of obesity-related disorders is a matter of debate.

Methods

In this study, we compare the long-term outcomes after bariatric with the presence of NAFLD in the liver biopsy at the time of surgery.

Results

The follow-up was available for 226 out of 288 patients. The mean follow-up time was 24.9 (± 13.6) months. The baseline histology showed that 112 patients (38.9%) had no NASH, 70 (24.3%) were borderline, and 106 (36.8%) had NASH. At follow-up, the mean BMI dropped from (52 ± 10.2) to (36.6 ± 8) kg/m 2. Excess weight loss (EWL) was similar in all NAFLD groups. Type 2 diabetes mellitus dropped from 35.7 to 11.4%, hypertension from 65.6 to 36.7%, hyperlipidemia from 62.3 to 33%, and obstructive sleep apnea from 37.5 to 14.9%.

Only hyperlipidemia was significantly associated with NASH compared to the groups with no NASH or borderline NASH (p value = 0.002 and p value = 0.04, respectively) during the first two years of follow-up.

Conclusion

The beneficial effects of bariatric surgery are evident across all patients with NAFLD. Patients with NASH have comparable outcomes regarding weight loss and resolution of obesity-related comorbidities.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00268-023-07153-8.

Publication and source details

Original title: The Effect of Non-Alcoholic Fatty Liver Disease on Weight Loss and Resolution of Obesity-Related Disorders After Bariatric Surgery

Thaer S. A. Abdalla; Anastasios D. Giannou; Ahmed S. A. Abdalla; Jakob R. Izbicki; Anna Dupreé; Oliver Mann; Stefan Wolter

World Journal of Surgery · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Universitätsklinikum Hamburg-Eppendorf (UKE) (5411)

Open Access funding enabled and organized by Projekt DEAL.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T16:20:10.997388+00:00

DOI: 10.1007/s00268-023-07153-8 · PMC10694115